Denali Therapeutics Inc. (DNLI)

Denali Therapeutics Revenue

Denali Therapeutics had revenue of $17.78M in the quarter ending September 30, 2026. This brings the company's total for the last twelve months to $21.38M. That makes Denali Therapeutics the 40,970th largest company in the world by revenue and 5,498th in the United States.

• Revenue (ttm): $21.38M
• Revenue Growth: n/a
• P/S Ratio: 145.40
• Revenue / Employee: $42,174
• Employees: 507
• Market Cap: 3.11B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Biogen Collaboration 295.53M 89.4%
• Sanofi Collaboration 25.00M 7.6%
• Takeda Collaboration 10.00M 3.0%

Fiscal year ended Dec 31, 2023 See the full Denali Therapeutics breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	-	-	-
Dec 31, 2024	-	-	-
Dec 31, 2023	330.53M	222.07M	204.74%
Dec 31, 2022	108.46M	59.80M	122.90%
Dec 31, 2021	48.66M	-287.00M	-85.50%

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Nov 3, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error